A recent paper is stirring up the antibody world—single-domain antibodies (sdAbs) are emerging as a powerful countermeasure as viral evolution outpaces conventional antibody therapies.

SHIRLEY, NY, July 29, 2025 /24-7PressRelease/ — A landmark Nature Communications study (May 2025) reported a panel of single-domain antibodies that broadly neutralize SARS-CoV-1 and -2 with unusually high potency, which underscores sdAbs’ unique capacity to bind even hidden epitopes—a capability now being leveraged across oncology, neurology, and infectious disease pipelines.

The enthusiasm grows, and so do the requests for reliable partners to help translate sdAb concepts into clinically available molecules. That’s where a biotechnology service provider, Creative Biolabs, is stepping in, providing end-to-end sdAb development solutions that simplify what has traditionally been a high-barrier field.

The sdAb Advantage: Small Size, Big Impact

sdAbs (12–15 kDa) derived from camelid VHH or shark VNAR domains offer distinct advantages:
• Deep tissue penetration (crossing the blood-brain barrier in CNS applications)
• Exceptional stability (maintain function in extreme pH/temperatures)
• Rapid clearance (ideal for imaging/theragnostic use)
• Low immunogenicity

Through its integrated platform, Creative Biolabs has capitalized on sdAbs’ exceptional properties, enabling precise engineering of sdAb architectures.

Building Smarter, Stronger Antibodies

1.Bispecific sdAb Development
Creative Biolabs can improve bsAb performance utilizing VHH antibodies as a source of specificity, which establish an optimal model because VHH antibodies possess a low molecular weight of approximately 15 kDa, along with enhanced penetration capabilities and high production yields. It is possible to create molecules with either two or multiple binding sites and one or more specificities when two or more VHH antibodies “bind” together.

2.Multivalent sdAb Engineering
The engineering solution enables researchers to create complicated formats with enhanced avidity and functional synergy—by linking multiple sdAb units targeting the same or different epitopes, such constructs can amplify therapeutic effect while retaining small-molecule-like properties including excellent penetrability, low immunogenicity, and favorable pharmacokinetics.

3. sdAb Libraries That Open Doors
Access to a diverse recombinant sdAb library is essential, especially for researchers still at the exploring stage. Creative Biolabs builds a well-characterized collection derived from camelid, shark, and synthetic sources, providing scientists with a head start in discovering binders to both conventional and undruggable targets.

4. From Bench to Bioreactor
The challenge shifts to production and scale-up once a lead candidate is confirmed. With their custom sdAb production and manufacturing service, Creative Biolabs can deliver high-yield expression in microbial or mammalian systems, supported by quality control, endotoxin testing, and downstream purification workflows.

“Our neutralizing sdAbs act like molecular pliers,” said a scientist, “which has been proved critical against SARS-CoV-2 variants and applies equally to RSV, HIV, and emerging pathogens.”

Visit https://www.creative-biolabs.com/sdab/ to learn more.

About
Creative Biolabs promises to provide sdAbs that have a small format and big impact.

—
For the original version of this press release, please visit 24-7PressRelease.com here